Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

Abstract

One hundred and ten patients with multiple myeloma were treated with bendamustine as part of a French compassionate use program. To receive bendamustine, patients had to present with relapsed or refractory disease after prior therapies that had to include alkylators, steroids, IMiDs and bortezomib. The median number of bendamustine cycles administered was 4 (1-13). The overall response rate (≥ partial response) was 30%, including 2% complete responses. The median progression-free and overall survival for the entire cohort were 9.3 and 12.4 months, respectively. In this series of patients with advanced disease, both the response rate and the duration of response are encouraging and indicate that bendamustine presents a feasible option, which should be considered for the treatment of relapsed/refractory patients.

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review

“…[21][22][23][24] Bendamustine is effective against indolent lymphomas, 25,26 chronic lymphocytic leukemia, mantle cell lymphoma, 27 large B-cell lymphomas, 28 peripheral T-cell lymphomas, 29,30 HLs [31][32][33] and multiple myelomas. [34][35][36] The doses used are 50-180 mg/m 2 on days 1 and 2 or a total dose of 100-360 mg/m 2 in a single intravenous perfusion over 30-60 min every 21-28 days. Digestive disorders and increased infectious toxicities were associated with higher doses.…”

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

“…Bendamustine is another option and has shown promising results in patients with advanced disease. 6 In the present phase II study, we investigated a triplet combination consisting of bortezomib, dexamethasone plus bendamustine (BVD) in elderly patients at the time of first relapse.…”

“…Since MPT is one of the combinations considered a standard of care for the front-line treatment of elderly patients (not eligible for ASCT), 1 and lenalidomide / lowdose dexamethasone, although not yet approved, also presents a very promising combination as part of first-line therapy in the same group of patients, 3 it is, therefore, logical to evaluate IMiD-free combination strategies that include bortezomib at the time of first relapse. The combination of bendamustine, which has previously demonstrated efficacy in the relapse setting, 6 with bortezomib and dexamethasone was, therefore, considered to be a good candidate to be tested in elderly patients at the time of first relapse.…”

“…Philippe Rodon, 1 Cyrille Hulin, 2 Brigitte Pegourie, 3 Mourad Tiab, 4 Bruno Anglaret, 5 Lotfi Benboubker,6 Henry Jardel, 7 Olivier Decaux, 8 Brigitte Kolb, 9 Murielle Roussel, 10 Laurent Garderet, 11 Xavier Leleu, 12 Olivier Fitoussi, 13 …”

Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation

“…Consistent with its non-cross resistance to other alkylating agents, he achieved good PR to this bendamustine combination. Indeed, recent studies of bendamustine/prednisolone in relapsed/refractory myeloma showed a modest response rate, 13 but much higher rate of response (60%) is achieved by combining bortezomib with bendamustine and dexamethasone.…”